EMA accepts MAA for avacincaptad pegol for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration
Astellas Pharma announced that European regulatory authorities have accepted for review a marketing authorization application for avacincaptad pegol for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Avacincaptad pegol is a complement C5 inhibitor acquired through the company’s $5.9 billion buyout of US eye drug specialist Iveric Bio.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) will now start its review of the application. The drug was approved in the US earlier this month under the brand name of Izervay.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins